Pharmacogenetics of cancer therapy: Getting personal

American Journal of Human Genetics

Volumn 63, Issue 1, 1998, Pages 11-16

  Krynetski, Eugene Y ^a   Evans, William E ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMONAFIDE; AZATHIOPRINE; BUSULFAN; CYCLOPHOSPHAMIDE; FLUOROURACIL; IRINOTECAN; MERCAPTOPURINE; TIOGUANINE;

CANCER GENETICS; CANCER THERAPY; ENZYME METABOLISM; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HISTORY OF MEDICINE; HUMAN; HUMAN CELL; HUMAN TISSUE; INDIVIDUALITY; PRIORITY JOURNAL; REVIEW;

EID: 0032231751     PISSN: 00029297     EISSN: None     Source Type: Journal    
DOI: 10.1086/301941     Document Type: Article

References (37)

1. Chang TK, Yu L, Goldstein JA, Waxman DJ (1997) Identification of the polymorphically expressed CYP2C19 and the wild type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosphamide activation. Pharmacogenetics 7:211-221
2. Chocair PR, Duley JA, Simmonds HA, Cameron JS (1992) The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients. Transplantation 53:1051-1056
3. Czerwinski M, Gibbs JP, Slattery JT (1996) Busulfan conjugation by glutathione S-transferases alpha, mu and pi. Drug Metab Dispos 24:1015-1019
4. Diasio RB, Beavers TL, Carpenter JT (1988) Familial deficiency of dihydropyrimidine dehydrogenase: biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 81:47-51
5. Elion GB (1989) The purine path to chemotherapy. Science 244:41-47
6. Evans WE, Horner M, Chu YQ, Kalwinsky D, Roberts WM (1991) Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr 119:985-989
7. Gonzalez FJ, Fernandez-Salguero P (1995) Diagnostic analysis, clinical importance and molecular basis of dihydropyrimidine dehydrogenase deficiency. Trends Pharmacol Sci 16: 325-327
8. Grant DM (1993) Molecular genetics of the N-acetyltransferases. Pharmacogenetics 3:45-50
9. Hartsough MT, Steeg PS (1998) Nm23-H1: genetic alterations and expression patterns in tumor metastasis. Am J Hum Genet 63:6-10 (in this issue)
10. Hollander AAM, van Saase JLCM, Kootte AMM, van Dorp WT, van Bockel HJ, van Es LA, van der Woude FJ, et al (1995) Beneficial effects of conversion from cyclosporin to azathioprine after kidney transplantation. Lancet 345: 610-614
11. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, Coffman BL, et al (1998) Genetic predisposition to the metabolism of irinotecan (CPT-11): role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 101:847-854
12. Krynetski EY, Schuetz JD, Galpin AJ, Pui CH, Relling MV, Evans WE (1995) A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci USA 92:949-953
13. Krynetski EY, Tai HL, Yates CR, Fessing MY, Loennechen T, Schuetz JD, Relling MV, et al (1996) Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics 6:279-290
14. Lennard L, Keen D, Lilleyman JS (1986) Oral 6-mercaptopurine in childhood leukemia: parent drug pharmacokinetics and active metabolite concentrations. Clin Pharmacol Ther 40:287-292
15. Lennard L, Lilleyman JS (1989) Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol 7:1816-1823 (Erratum [1990] J Clin Oncol 8:567)
16. Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM (1990) Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 336: 225-229
17. McLeod HL, Lin JS, Scott EP, Pui CH, Evans WE (1994) Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther 55:15-20
18. McLeod HL, Miller DR, Evans WE (1993) Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet 341:1151
19. McLeod HL, Relling MV, Liu Q, Pui CH, Evans WE (1995) Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood 85:1897-1902
20. Meyer UA, Zanger UM (1997) Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 37:269-296
21. Narod SA (1998) Host susceptibility to cancer progression. Am J Hum Genet 63:1-5 (in this issue)
22. Nebert DW (1997) Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist? Am J Hum Genet 60:265-271
23. Nebert DW, McKinnon RA, Puga A (1996) Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. DNA Cell Biol 15:273-280
24. Otterness D, Szumlanski C, Lennard L, Klemetsdal B, Aarbakke J, Park-Hah JO, Iven H, et al (1997) Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther 62:60-73
25. Ratain MJ, Mick R, Berezin F, Janish L, Schilsky RL, Williams SF, Smiddy J (1991) Paradoxical relationship between acetylator phenotype and amonafide toxicity. Clin Pharmacol Ther 50:573-579
26. Schutz E, Gummert J, Mohr F, Oellerich M (1993) Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet 341:436
27. Szumlanski CL, Honchel R, Scott MC, Weinshilboum RM (1992) Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes. Pharmacogenetics 2: 148-159
28. Szumlanski C, Otterness D, Her C, Lee D, Brandriff B, Kelsell D, Spurr N, et al (1996) Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol 15:17-30
29. Tai HL, Krynetski EY, Schuetz EG, Yanishevski Y, Evans WE (1997) Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. Proc Natl Acad Sci USA 94: 6444-6449
30. Tai H-L, Krynetski EY, Yates CR, Loennechen T, Fessing MY, Krynetskaia NF, Evans WE (1996) Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet 58:694-702
31. Van Loon JA, Szumlanski CL, Weinshilboum RM (1992) Human kidney thiopurine methyltransferase: photoaffinity labeling with S-adenosyl-L-methionine. Biochem Pharmacol 44:775-785
32. Van Loon JA, Weinshilboum RM (1982) Thiopurine methyltransferase biochemical genetics: human lymphocyte activity. Biochem Genet 20:637-658
33. Wei X, McLeod HL, McMurrough J, Gonzalez FJ, Fernandez-Salguero P (1996) Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest 98:610-615
34. Weinshilboum RM, Raymond FA, Pazmino PA (1978) Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties. Clin Chim Acta 85: 323-333
35. Weinshilboum RM, Sladek SL (1980) Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 32: 651-662
36. Woodson LC, Dunnette JH, Weinshilboum RM (1982) Pharmacogenetics of human thiopurine methyltransferase: kidney-erythrocyte correlation and immunotitration studies. J Pharmacol Exp Ther 222:174-181
37. Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL, Pui CH, Relling MV, et al (1997) Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 126:608-614